You are here: Industry Insights > GlobalData

News List

AI, big data will continue to disrupt pharma sector, say healthcare industry professionals in GlobalData survey expresspharma
July 19, 2021
The COVID-19 pandemic has given businesses an unprecedented opportunity to implement technology-fueled changes to the way they operate.
2021 is a key year for personalised neoantigen immuno-oncology therapeutics: GlobalData expresspharma
July 15, 2021
The four molecules expected to launch first, autogene cevumeran, GRANITE-001, ATL001, and Genocea Biosciences’ GEN-009 have combined peak forecast sales of over $1 billion by 2027.
COVID-19 vaccine market set to reach $19.5 bn by 2026: GlobalData expresspharma
July 15, 2021
COVID-19 vaccines based on mRNA technology dominate the 7MM in 2021 with a market share of 95.4 per cent and $9.5 billion in sales for Pfizer/BioNTech and $3.5 billion for Moderna.
Global adult epilepsy market to reach $8.35 billion by 2023: GlobalData expresspharma
July 09, 2021
The adult epilepsy market is expected to grow from $5.82 billion in 2020 to $8.35 billion by 2030 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 3.7 per cent, according to GlobalData.
Sales of long-acting immunosuppressants for non-infectious uveitis to touch $357 mn by 2029: GlobalData expresspharma
July 06, 2021
Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects.
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData expresspharma
July 05, 2021
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with six of these being topical formulations.
Opportunities remain to address unmet needs in cystic fibrosis therapeutics market: GlobalData expresspharma
July 05, 2021
CFTR modulators are currently the only available treatments that target the underlying cause of CF. However, some patients with rare CFTR mutations are still ineligible to receive currently marketed therapies.
Patient access to gene therapies for cancer likely to increase in the next decade: GlobalData expresspharma
June 29, 2021
These therapies are expected to eliminate the need for further treatments and reduce the cost of disease management.
New products to drive systemic sclerosis market to $1.8 bn by 2030: GlobalData expresspharma
June 21, 2021
GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024, respectively.
Chinese patent reforms to bolster pharma innovation europeanpharmaceuticalreview
June 18, 2021
Market research suggests the new drug patent reforms in China, in addition to other regulatory changes, will incentivise innovative pharma research.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page